Laura Steele was appointed Senior Vice President, US Neuroscience for Eli Lilly and Company in 2024. Steele leads Lilly’s neuroscience business unit (NBU) commercial operations for the United States and is responsible for all aspects of NBU US sales and marketing. Steele was previously President and General Manager (GM) of Eli Lilly and Company UK, Ireland & Northern Europe, where she oversaw business operations across the company’s Diabetes, Oncology, Immunology and Neuroscience portfolio in six countries. Laura served on the Association of the British Pharmaceutical Industry and as Vice Chair for the American Pharmaceutical Group shaping policy change within the UK. With over two decades worth experience at Lilly, she has held a variety of roles, including in Lilly’s Corporate Business Development division in the US, Marketing, Value & Access. Laura is currently a Board Member for the Alzheimer’s Drug Discovery Foundation Board and Ascencion St. Vincent Indianapolis. An insightful and authentic leader, Laura is a champion of diversity and inclusion initiatives and is passionate about developing talent and building high-performing teams. Laura’s 21-year career at Lilly spans sales, payer and marketing roles, where she built a reputation for a tenacious approach to innovation and her unfaltering commitment to patient-centricity. Under Laura’s leadership, the company’s Migraine Marketing division in Indianapolis accomplished multiple company and industry firsts, including projects in telemedicine and digital marketing.